Biovaxys Technology Corp (TSE:BIOV) has released an update.
BioVaxys Technology Corp., a clinical-stage biopharmaceutical company, has announced a delay in filing its annual and interim financial statements due to the extended time required for auditing, particularly after its recent acquisition of IMV Inc.’s assets. The management cease trade order will remain in place until the company files the required documents, which is expected by April 30, 2024. No insolvency proceedings are underway and there are no undisclosed material changes since the last announcement.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
